Drug Trial Radar · NCT06827236
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
380
Planned (sponsor's estimate)
Start
Apr 23, 2025
Primary completion
Aug 2029
Study completion Aug 2029
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- DualityBio Inc.; BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
- First posted
- Feb 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination with BNT327 (also known as pumitamig and PM8002) in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth factor receptor (HER)2-positive, HER2-low (immunohistochemistry \[IHC\] 1+ or IHC 2+/in situ hybridization -), HER2-ultralow (IHC 0, with membrane staining) or HER2-null breast cancer (BC), or triple-negative breast cancer (TNBC).
Conditions
- Locally Advanced Breast Cancer
- Unresectable Breast Carcinoma
- Metastatic Breast Cancer
Interventions
BNT323Drug
Intravenous infusion
BNT327Drug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - Occurrence of dose limiting toxicities (DLTs)Time frame: During the DLT evaluation period (Cycle 1), i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days
- Occurrence of Treatment-emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEsTime frame: From the time of initiation of the first dose of IMP to 90 days after the last IMP dose
- Occurrence of dose interruption, reduction, and discontinuation due to TEAEsTime frame: From the time of initiation of the first dose of IMP to 90 days after the last IMP dose
- Part 2 - Objective response rate (ORR)Time frame: From the time of initiation of the first dose of IMP to last tumor assessment scan, i.e., up to 36 months.
Locations
84 sites in 11 countries. Site status is shown where the registry gives one.
Beverly Hills Cancer Center
Beverly Hills, California · Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, California · Recruiting
Hematology - Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida · Recruiting
University Cancer & Blood Center, LLC
Athens, Georgia · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
University of Illinois Hospital & Health Sciences System
Chicago, Illinois · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Brigitte Harris Cancer Pavilion BHCP
Detroit, Michigan · Recruiting
START Midwest, LLC
Grand Rapids, Michigan · Recruiting
Saint Luke's Hospital of Kansas City
Kansas City, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Memorial Sloan Kettering Cancer Center Basking Ridge
Basking Ridge, New Jersey · Recruiting
Summit Medical Group
Florham Park, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center Monmouth
Middletown, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center Bergen
Montvale, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center Westchester
Harrison, New York · Recruiting
Beth Israel Comprehensive Cancer Center
New York, New York · Recruiting
Mount Sinai Medical Center
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai PRIME
New York, New York · Recruiting
Memorial Sloan Kettering Hospital
New York, New York · Recruiting
Memorial Sloan Kettering Commack
New York, New York · Recruiting
Stony Brook University Hospital
Stony Brook, New York · Recruiting
Memorial Sloan Kettering Cancer Center Nassau
Uniondale, New York · Recruiting
Greco Hainsworth Center for Research Tennessee Oncology
Nashville, Tennessee · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Baylor Scott & White Research Institute -Texas Oncology
Dallas, Texas · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
South Texas Accelerated Research Therapeutics (START), LLC
San Antonio, Texas · Recruiting
University of Wisconsin
Madison, Wisconsin · Recruiting
Cancer Research SA
Adelaide, Australia · Recruiting
Box Hill Hospital
Box Hill, Australia · Recruiting
St Vincent s Hospital Melbourne
Fitzroy, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Australia · Recruiting
CIUSSS du Saguenay-Lac-Saint-Jean
Chicoutimi, Canada · Recruiting
London Health Sciences Centre (LHSC) - Victoria Hospital
London, Canada · Recruiting
Sunnybrook Health Sciences Centre
Toronto, Canada · Recruiting
BC Cancer - Vancouver
Vancouver, Canada · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China · Recruiting
Jilin Cancer Hospital
Changchun, China · Recruiting
Sichuan Cancer Hospital
Chengdu, China · Recruiting
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.